OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes announces plans to demonstrate its SlimBiome® products to shareholders.
The Company reported a breakthrough in the manufacture of its SweetBiotix products on 24 November 2025 leading to higher yields of purer, more concentrated, better tasting product with lower ingredient and production costs.
The Company is now in a position to demonstrate this product to shareholders at an event in London to be held in June 2026, subject to the availability of a suitable venue. In order to assess attendance and venue size, the Company would encourage all existing shareholders and prospective investors who are interested in attending to sign up (it should take less than one minute) using the link below:-
1. Visit https://optibiotix.com/s/3eda67
2. Follow the prompts on the top right hand side of the website marked SIGN UP
3. Complete your account profile (name/email address)
Once registered, OptiBiotix can update investors on location and timings and send invitations to interested shareholders. The meeting will give an overview of the commercial progress of the Company’s first generation products , second generation products and their route to market, and sampling of SweetBiotix.
|
For further information, please contact: OptiBiotix Health plc |
||
|
Neil Davidson, Chairman |
|
|
|
Stephen O’Hara, Chief Executive |
||
|
|
||
About OptiBiotix : www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), OptiBiotix Health has developed a range of technologies and commercialised products which modulate the human microbiome to help prevent and manage human disease. Since the Group’s inception it has created a wide range of microbiome-based ingredients and products including prebiotic products like SlimBiome®, WellBiome®, SweetBiotix® and Microbiome Modulators within its core OptiBiotix Health plc (OPTI) business, but also skincare through its holdings in SkinBioTherapeutics PLC (SBTX), and probiotics through ProBiotix Health plc (PBX). These companies create a diverse portfolio technologies and products in an emerging area of healthcare that is of growing interest in consumer markets throughout the world.
